Critical Role of Interleukin-17/interleukin-17 Receptor Axis in Mediating Con A-induced Hepatitis
Overview
Cell Biology
Authors
Affiliations
Concanavalin A (Con A)-induced hepatitis is thought to be a T-cell-mediated disease with active destruction of liver cells. Interleukin (IL)-17 is a cytokine produced principally by CD4(+) T cells. However, whether IL-17/IL-17 receptor (IL-17/IL-17R)-mediated responses are involved in T-cell-mediated Con A-induced liver injury remains unclear. In this study, we found that IL-17 expression was highly elevated in liver tissues during Con A-induced hepatitis. The increased levels of IL-17 were paralleled with the severity of liver injury reflected by Alanine aminotransaminase and histological assay as well as the secretion of tumor necrosis factor (TNF)-α and IL-6. Blockage of IL-17 significantly ameliorated Con A-induced hepatitis, while overexpression of IL-17 systemically resulted in massive hepatocyte necrosis in mice. Furthermore, overexpression of an IL-17R immunoglobulin G1 fusion protein significantly attenuated liver inflammation after acute Con A treatment. High expression of IL-17R on Kupffer cells was also observed along with the production of cytokines including TNF-α and IL-6. Inhibition of Kupffer cells by gadolinium chloride completely prevented Con A-induced liver injury and cytokine release. Finally, IL-17-expressing CD4(+) T and natural killer T cells were greatly increased in Con A-injected mice compared with that in controls. Overall, our results indicate that IL-17R signaling is critically involved in the pathogenesis in Con A-induced hepatitis, and blockade of IL-17/IL-17R signaling pathway may represent a novel therapeutic intervention in human autoimmune-related hepatitis.
Abdelnabi M, Hassan G, Shoukry N Front Immunol. 2024; 15:1437046.
PMID: 39156888 PMC: 11327067. DOI: 10.3389/fimmu.2024.1437046.
Tan S, Lu X, Chen W, Pan B, Kong G, Wei L Sci Rep. 2024; 14(1):6423.
PMID: 38494504 PMC: 10944831. DOI: 10.1038/s41598-024-57139-2.
Shaker M, Gomaa H, Hazem S, Abdelgawad M, El-Mesery M, Shaaban A Front Pharmacol. 2023; 14:1212771.
PMID: 37608890 PMC: 10441125. DOI: 10.3389/fphar.2023.1212771.
Vujovic A, Isakovic A, Misirlic-Dencic S, Juloski J, Mirkovic M, Cirkovic A Int J Mol Sci. 2023; 24(15).
PMID: 37569857 PMC: 10419971. DOI: 10.3390/ijms241512483.
Yang X, Zong C, Feng C, Zhang C, Smirnov A, Sun G Adv Sci (Weinh). 2023; 10(27):e2300424.
PMID: 37544916 PMC: 10520691. DOI: 10.1002/advs.202300424.